NASDAQ:DCTH

Delcath Systems Stock Forecast, Price & News

$10.20

+0.32 (+3.24 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.74

▼

$10.63

50-Day Range

$8.90

▼

$12.65

52-Week Range

$8.78

▼

$25.18

Volume25,825 shs

Average Volume56,527 shs

Market Capitalization$71.60 million

P/E RatioN/A

Dividend YieldN/A

Beta0.56

30 days | 90 days | 365 days | Advanced Chart

Receive DCTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Global Fuel Management Systems Market to Reach US$814.3 Million by the Year 2027
July 29, 2021 | in.finance.yahoo.com

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results
July 28, 2021 | finance.yahoo.com

Delcath Systems, Inc. Common Stock (DCTH)
July 18, 2021 | nasdaq.com

Delcath Systems (NASDAQ:DCTH) & Cardiovascular Systems (NASDAQ:CSII) Financial Analysis
July 17, 2021 | americanbankingnews.com

Ernest C. Garcia II Sells 41,491 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) Stock
July 15, 2021 | americanbankingnews.com

Contrasting Delcath Systems (NASDAQ:DCTH) & Sensus Healthcare (NASDAQ:SRTS)
July 11, 2021 | americanbankingnews.com

Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET
July 7, 2021 | finance.yahoo.com

Return On Capital Employed Overview: Delcath Systems
June 17, 2021 | benzinga.com

Delcath Systems Set to Join Russell Microcap® Index
June 8, 2021 | finance.yahoo.com

Delcath Systems' Hepzato Achieves 44% Best Overall Response Compared to Best Alternative Care in Eye Cancer
June 7, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCTH
Previous Symbol
CUSIPN/A
CIK872912
Webdelcath.com
Phone212 489 2100
Employees36
Year FoundedN/A

Sales & Book Value

Annual Sales$1.16 million
Price / Sales61.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.68 per share
Price / Book2.77

Profitability

EPS (Most Recent Fiscal Year)($8.35)
Net Income$-24,160,000.00
Net Margins-1,551.65%
Return on Equity-173.70%
Return on Assets-88.66%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares7,020,000
Market Cap$71.60 million
Next Earnings Date8/10/2021 (Confirmed)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.33 out of 5 stars

Medical Sector

113th out of 842 stocks

Surgical & Medical Instruments Industry

11th out of 74 stocks

3.5 Analyst's Opinion

Consensus Rating
Delcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.00, Delcath Systems has a forecasted upside of 135.3% from its current price of $10.20.
Amount of Analyst Coverage
Delcath Systems has only been the subject of 1 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Delcath Systems has received 10 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Delcath Systems has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Delcath Systems has received 83.33% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Delcath Systems and other stocks. Vote “Outperform” if you believe DCTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DCTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Delcath Systems does not currently pay a dividend.
Dividend Growth
Delcath Systems does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $364,182.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.43% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.56% of the stock of Delcath Systems is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Delcath Systems are expected to grow in the coming year, from ($3.90) to ($2.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Delcath Systems is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Delcath Systems is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Delcath Systems has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Delcath Systems (NASDAQ:DCTH) Frequently Asked Questions

Is Delcath Systems a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Delcath Systems stock.
View analyst ratings for Delcath Systems or view top-rated stocks.

What stocks does MarketBeat like better than Delcath Systems?

Wall Street analysts have given Delcath Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Delcath Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Delcath Systems' next earnings date?

Delcath Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Delcath Systems.

How can I listen to Delcath Systems' earnings call?

Delcath Systems will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) announced its earnings results on Tuesday, May, 11th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.15. The business earned $0.39 million during the quarter, compared to analyst estimates of $0.38 million. Delcath Systems had a negative net margin of 1,551.65% and a negative trailing twelve-month return on equity of 173.70%.
View Delcath Systems' earnings history.

How has Delcath Systems' stock price been impacted by Coronavirus (COVID-19)?

Delcath Systems' stock was trading at $9.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DCTH stock has increased by 10.9% and is now trading at $10.20.
View which stocks have been most impacted by COVID-19.

When did Delcath Systems' stock split? How did Delcath Systems' stock split work?

Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 1 shares after the split.

What price target have analysts set for DCTH?

3 brokerages have issued 12-month target prices for Delcath Systems' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Delcath Systems' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Delcath Systems or view top-rated stocks among Wall Street analysts.

Who are Delcath Systems' key executives?

Delcath Systems' management team includes the following people:

Mr. Gerard J. Michel, CEO & Director (Age 58, Pay $132k)
Mr. John Purpura M.S., Chief Operating Officer (Age 60, Pay $437.37k)
Ms. Christine Padula, Interim Principal Accounting Officer (Age 56, Pay $200.3k)
Mr. Thomas Johnson, Sr. Director of Corp. Communications
Mr. Robin Wagge, Sr. VP of Rubenstein Associates
Dr. Johnny John M.D., Sr. VP Clinical Devel. & Medical Affairs

Who are some of Delcath Systems' key competitors?

Some companies that are related to Delcath Systems include DarioHealth (DRIO), Apollo Endosurgery (APEN), TELA Bio (TELA), Titan Medical (TMDI), Beyond Air (XAIR), Nemaura Medical (NMRD), T2 Biosystems (TTOO), Repro Med Systems (KRMD), RenovaCare (RCAR), BrainsWay (BWAY), PolyPid (PYPD), Repro-Med Systems (REPR), Venus Concept (VERO), Liquidia (LQDA) and Pro-Dex (PDEX).
View all of DCTH's competitors.

What is Delcath Systems' stock symbol?

Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."

How do I buy shares of Delcath Systems?

Shares of DCTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Delcath Systems' stock price today?

One share of DCTH stock can currently be purchased for approximately $10.20.

How much money does Delcath Systems make?

Delcath Systems has a market capitalization of $71.60 million and generates $1.16 million in revenue each year. The company earns $-24,160,000.00 in net income (profit) each year or ($8.35) on an earnings per share basis.

How many employees does Delcath Systems have?

Delcath Systems employs 36 workers across the globe.

What is Delcath Systems' official website?

The official website for Delcath Systems is delcath.com.

Where are Delcath Systems' headquarters?

Delcath Systems is headquartered at 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company can be reached via phone at 212 489 2100 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here